Treatment with the chimeric anti-IL-2Ralpha basiliximab affects both the IL-2 and IL-15 signalling pathways after clinical kidney transplantation

Transplant Proc. 2001 Feb-Mar;33(1-2):1007-8. doi: 10.1016/s0041-1345(00)02306-x.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Basiliximab
  • Cyclosporine / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Interleukin-15 / immunology*
  • Interleukin-2 / immunology*
  • Kidney Transplantation*
  • Mycophenolic Acid / analogs & derivatives
  • Mycophenolic Acid / therapeutic use
  • Prednisolone / therapeutic use
  • Receptors, Interleukin-2 / immunology
  • Recombinant Fusion Proteins*
  • Signal Transduction / drug effects*
  • T-Lymphocytes / drug effects*
  • T-Lymphocytes / immunology

Substances

  • Antibodies, Monoclonal
  • Immunosuppressive Agents
  • Interleukin-15
  • Interleukin-2
  • Receptors, Interleukin-2
  • Recombinant Fusion Proteins
  • Cyclosporine
  • Basiliximab
  • Prednisolone
  • Mycophenolic Acid